The startup develops therapeutic drugs utilizing isoform-selective histone deacetylase enzyme inhibitors, specifically targeting HDAC6 to restore normal protein function. Their approach aims to treat peripheral neuropathy, sickle cell disease, and beta-thalassemia by modifying disease progression at the molecular level.
Funding
$47.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Peripheral neuropathy, sickle cell disease, and beta-thalassemia are debilitating conditions with limited effective treatment options. These diseases often involve abnormal protein function, leading to disease progression at the molecular level.
Solution
The startup is developing therapeutic drugs based on isoform-selective histone deacetylase (HDAC) enzyme inhibitors. Their approach specifically targets HDAC6, an enzyme involved in regulating protein function, to restore normal cellular processes. By selectively inhibiting HDAC6, the drugs aim to modify the underlying mechanisms of disease progression in peripheral neuropathy, sickle cell disease, and beta-thalassemia. This targeted approach has the potential to offer more effective and specific treatments for these conditions.
Target Audience
The primary target audience includes patients suffering from peripheral neuropathy, sickle cell disease, and beta-thalassemia, as well as the healthcare providers who treat them.
Features
- Utilizes isoform-selective HDAC inhibitors
- Specifically targets HDAC6 enzyme
- Aims to restore normal protein function
- Designed to modify disease progression at the molecular level